Personalizing Chemotherapy for Black Women
Due in part to underrepresentation in clinical trials, Black women in the U.S. are at higher risk from dying of breast cancer than white women. Komen Scholar Bryan Schneider, M.D., trial lead for the EAZ171 clinical trial, is seeking to overcome these disparities in outcomes for Black women with breast cancer by personalizing chemotherapy.